论文部分内容阅读
目的探讨冠心病患者血清载脂蛋白A5(APOA5)与脂联素和空腹胰岛素(FINS)之间的关系。方法检测2005年6月至12月在中南大学湘雅二医院心内科住院确诊的51例冠心病患者和同期在此院门诊进行健康体检的44名健康对照者血清APOA5、脂联素、FINS和血脂,并计算胰岛素抵抗指数(HOMA-IR)。结果冠心病组血清APOA5和脂联素显著低于健康对照组[(230.06±115.80)μg/L对(324.43±151.79)μg/L,(3.03±1.85)mg/L对(4.12±2.48)mg/L,P均<0.05];冠心病组的FINS显著高于对照组[(9.85±5.94)mU/L对(7.85±3.04)mU/L,P<0.05]。APOA5与三酰甘油(TG)、FINS、HOMA-IR呈负相关,与高密度脂蛋白胆固醇(HDL-C)呈正相关,与脂联素不相关。结论冠心病患者血清APOA5和脂联素降低,FINS增高。APOA5不但影响血脂代谢,而且可能与胰岛素抵抗有关。
Objective To investigate the relationship between serum apolipoprotein A5 (APOA5) and adiponectin and fasting insulin (FINS) in patients with coronary heart disease. Methods The serum level of APOA5, adiponectin, adiponectin and adiponectin in 51 CHD patients admitted to Department of Cardiology, Second Xiangya Hospital of Central South University from January 2005 to December 2005 and 44 healthy controls in this hospital were analyzed. Lipids, and calculate the insulin resistance index (HOMA-IR). Results Serum levels of APOA5 and adiponectin in CHD patients were significantly lower than those in healthy controls [(230.06 ± 115.80) μg / L vs. (324.43 ± 151.79) μg / L vs (3.03 ± 1.85) mg / L vs. (4.12 ± 2.48) mg / L, all P <0.05]. FINS in CHD group was significantly higher than that in control group [(9.85 ± 5.94) mU / L vs (7.85 ± 3.04) mU / L, P <0.05]. APOA5 was negatively correlated with triglyceride (TG), FINS, HOMA-IR and positively correlated with high density lipoprotein cholesterol (HDL-C), but not with adiponectin. Conclusion Serum levels of APOA5 and adiponectin in patients with coronary heart disease are lower and FINS are higher. APOA5 not only affects blood lipid metabolism, but also may be related to insulin resistance.